Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for Alzheimer therapeutics

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 9, 2005, Pages 743-753

  Morgan, Dave ^a   Gordon, Marcia N ^a   Tan, Jun ^a,b   Wilcock, Donna ^a   Rojiani, Amyn M ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer; Amyloid; Amyloid precursor protein (APP); Apoptosis; Inflammation; Microglia; Necrosis; Phagocytosis

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ANTIBODY; CELL MARKER; CURCUMIN; DEXAMETHASONE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; LIPOPOLYSACCHARIDE; NITROFERULOFLURBIPROFEN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AGED; AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; BRAIN INJURY; CELL ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT INHIBITION; DRUG EFFECT; GENE OVEREXPRESSION; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; TRANSGENIC ANIMAL; TRANSGENIC MOUSE; VACCINATION;

EID: 24644438615     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000178444.33972.e0     Document Type: Review

References (84)

1. Akiyama H, Barger S, Bamum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421
2. Eikelenboom P, Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol Aging 1996;17:673-80
3. Dickson DW, Lee SC, Mattiace LA, et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 1993;7:75-83
4. Halliday G, Robinson SR, Shepherd C, et al. Alzheimer's disease and inflammation: A review of cellular and therapeutic mechanisms. Clin Exp Pharmacol Physiol 2000;27:1-8
5. Rogers J, Strohmeyer R, Kovelowski CJ, et al. Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 2002;40: 260-69
6. Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol 2002;72:233-38
7. Streit WJ. Microglia and Alzheimer's disease pathogenesis. J Neurosci Res 2004;77:1-8
8. Schenk DB, Yednock T. The role of microglia in Alzheimer's disease: Friend or foe? Neurobiol Aging 2002;23:677-79
9. Ard MD, Cole GM, Wei J, et al. Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. J Neurosci Res 1996;43:190-202
10. Webster SD, Yang AJ, Margol L, et al. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol 2000;161: 127-38
11. 1 integrin-dependent mechanism. J Neurosci 2004;24: 9838-46
12. Rogers J, Luber-Narod J, Styren SD, et al. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease. Neurobiol Aging 1988;9:339-49
13. Masliah E, Sisk A, Mallory M, et al. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996;16:5795-811
14. Frautschy SA, Yang F, Irrizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 1998;152:307-17
15. Stalder M, Phinney A, Probst A, et al. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 1999; 154:1673-84
16. Stalder M, Deller T, Staufenbiel M, et al. 3D-feconstruction of microglia and amyloid in APP23 transgenic mice: No evidence of intracellular amyloid. Neurobiol Aging 2001;22:427-34
17. Bornemann KD, Wiederhold KH, Pauli C, et al. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 2001;158:63-7
18. Sasaki A, Shoji M, Harigaya Y, et al. Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. Virchows Arch 2002;441:358-67
19. Matsuoka Y, Picciano M, Malester B, et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol 2001;158:1345-54
20. Fonseca MI, Zhou J, Botto M, et al. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 2004;24:6457-65
21. Gordon MN, Holcomb LA, Jantzen PT, et al. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 2002;173:183-95
22. Wilcock DM, Gordon MN, Ugen KE, et al. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 2001;20:731-36
23. Benzing WC, Wujek JR, Ward EK, et al. Evidence for glial-mediated inflammation in APPsw transgenic mice. Neurobiol Aging 1999;20: 581-90
24. Mehlhom G, Hollbom M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 2000;18:423-31
25. Tehranian R, Hasanvan H, Iverfeldt K, et al. Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576. Neurosci Lett 2001;301:54-8
26. Apelt J, Schliebs R. Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. Brain Res 2001;894: 21-30
27. Abbas N, Bednar I, Mix E, et al. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol 2002; 126:50-7
28. Fassbender K, Walter S, Kuhl S, et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J 2004;18:203-5
29. Bondolfi L, Calhoun M, Ermini F, et al. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci 2002;22:515-22
30. Irizarry MC, McNamara M, Fedorchak K, et al. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 1997;56:965-73
31. Irizarry MC, Soriano F, McNamara M, et al. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J Neurosci 1997;17:7053-59
32. DiCarlo G, Wilcock D, Henderson D, et al. Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice. Neurobiol Aging 2001;22:1007-12
33. Herber DL, Roth LM, Wilson D, et al. Time-dependent reduction in Abeta levels after intracranial LPS administration in APP transgenic mice. Exp Neurol 2004;190:245-53
34. Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-32
35. Quinn J, Montine T, Morrow J, et al. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 2003;137:32-41
36. Malm TM, Koistinaho M, Parepalo M, et al. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis 2005;18:134-42
37. Qiao X, Cummins DJ, Paul SM. Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse. Eur J Neurosci 2001;14:474-82
38. Sly LM, Krzesicki RF, Brashler JR, et al. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull 2001;56:581-88
39. Sheng JG, Bora SH, Xu G, et al. Lipopolysaccharide-induced-neuro- inflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 2003;14:133-45
40. Breitner JC, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? N Engl J Med 2001;345:1567-68
41. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000;20:5709-14
42. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-54
43. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-77
44. Yan JJ, Cho JY, Kim HS, et al. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 2001;133:89-96
45. Gasparini L, Ongini E, Wilcock DM, et al. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease. Brain Res Rev 2005;48:400-8
46. Lesne S, Docagne F, Gabriel C, et al. Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem 2003;278:18408-18
47. Wyss-Coray T, Masliah E, Mallory M, et al. Amyloidogenic role of cytokine TGF-beta 1 in transgenic mice and in Alzheimer's disease. Nature 1997;389:603-6
48. Wyss-Coray T, Lin C, Yan F, et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med 2001;7:612-18
49. Wyss-Coray T, Yan F, Lin AH, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A 2002;99:10837-42
50. Roberts GW, Gentleman SM, Lynch A, et al. Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1994;57:419-25
51. Nakagawa Y, Nakamura M, McIntosh TK, et al. Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. J Comp Neurol 1999;411:390-98
52. Nakagawa Y, Reed L, Nakamura M, et al. Brain trauma in aged transgenic mice induces regression of established abeta deposits. Exp Neurol 2000;163:244-52
53. Uryu K, Laurer H, McIntosh T, et al. Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J Neurosci 2002;22:446-54
54. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-77
55. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-85
56. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-19
57. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-β deposits in living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-72
58. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002;22:7873-78
59. Wilcock DM, DiCarlo G, Henderson D et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J.Neurosci 2003;23:3745-51
60. Wilcock DM, Munireddy SK, Rosenthal A, et al. Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration. Neurobiol Dis 2004;15:11-20
61. Solomon B, Koppel R, Hanan E, et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A 1996;93:452-55
62. Das P, Howard V, Loosbrock N, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci 2003;23:8532-38
63. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004;24:6144-51
64. Koistinaho M, Koistinaho J. Role of p38 and p44/42 mitogen-activated protein kinases in microglia. Glia 2002;40:175-83
65. Garcia-Garcia E, Rosales R, Rosales C. Phosphatidylinositol 3-kinase and extracellular signal-regulated kinase are recruited for Fc receptor-mediated phagocytosis during monocyte-to-macrophage differentiation. J Leukoc Biol 2002;72:107-14
66. Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine- specific clearance of apoptotic cells. Nature 2000;405:85-90
67. Magnus T, Chan A, Savill J, et al. Phagocytotic removal of apoptotic, inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 2002;130:1-9
68. Roos A, Xu W, Castellano G, et al. Mini-review: A pivotal role for innate immunity in the clearance of apoptotic cells. Eur J Immunol 2004;34:921-29
69. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-51
70. Duffield JS. The inflammatory macrophage: A story of Jekyll and Hyde. Clin Sci (Lond) 2003;104:27-38
71. Mills CD, Kincaid K, Alt JM, et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000;164:6166-73
72. Bastos KR, Alvarez JM, Marinho CR, et al. Macrophages from IL-12p40-deficient mice have a bias toward the M2 activation profile. J Leukoc Biol 2002;71:271-78
73. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55
74. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004;25:677-86
75. Dijstelbloem HM, van de Winkel JG, Kallenberg CG. Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 2001;22:510-16
76. Barger SW. Vascular consequences of passive Abeta immunization for Alzheimer's disease. Is avoidance of 'malactivation' of microglia enough? J Neuroinflammation 2005;2:2
77. Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-57
78. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-54
79. Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 2003;74:142-47
80. Stalder M, Phinney A, Probst A, et al. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol 1999;154:1673-84
81. Bornemann KD, Wiederhold KH, Pauli C, et al. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol 2001;158:63-7
82. Murphy GM Jr, Zhao F, Yang L, et al. Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease. Am J Pathol 2000;157:895-904
83. Apelt J, Lessig J, Schliebs R. Beta-amyloid-associated expression of intercellular adhesion molecule-1 in brain cortical tissue of transgenic Tg2576 mice. Neurosci Lett 2002;329:111-15
84. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflamm 2004;1:24